Citations

Clear

16280 citation(s) found for "Yu, David".

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment
Oomens, Julie Elisabeth , Biber, Sarah , Albert, Marilyn, Alosco, Michael L. , Arfanakis, Konstantinos , Brewer, James B., Chin, Erin, Clark, Lindsay R. , Cohen, Ann D. , Dage, Jeffrey L. , Detre, John A. , DiFilippo, Frank P. , Dyck, Christopher H. van , Grabowski, Thomas J. , Habes, Mohamad, Hedden, Trey , Jagust, William, Jefferson, Angela L. , Kecskemeti, Steven , Kantarci, Kejal, Keene, Dirk, Knoefel, Janice E. , Lin, Weili, Masurkar, Arjun V. , Morhardt, Darby, Okonkwo, Ozioma C. , Rabinovici, Gil D. , Rahman‐Filipiak, Annalise , Reiman, Eric M., Risacher, Shannon L. , Rosen, Howie, Schneider, Lon S. , Song, Allen W. , Swerdlow, Russell H. , Vaillancourt, David E. , Villemagne, Victor L. , Qiu, Deqiang , Foroud, Tatiana, Mormino, Elizabeth C. , Kantarci, Kejal , Oomens, Julie E , Kantarci, Kejal , Rabinovici, Gil D , Dage, Jeffrey L , Cohen, Annie , Benzinger, Tammie L.S. , Burns, Jeffrey M. , Chin, Nathaniel A. , Dickerson, Bradford Clark , Donohue, Michael , Fan, Audrey Peiwen , Habes, Mohamad , Harrison, Theresa M. , Hohman, Timothy J. , Jicha, Gregory A. , Kukull, Walter A. , Lin, Weili , Lao, Patrick , Lepping, Rebecca J. , Levendovszky, Swati Rane , McConathy, Jonathan , Mindt, Mónica Rivera , Noll, Douglas C. , Parrish, Todd B. , Reiman, Eric M. , Rudolph, Marc D. , Silbert, Lisa C. , Stark, Craig E.L. , Thompson, Paul M. , Wolk, S. J. , Johnson, Sterling C.

Mayo Clinic

Alzheimer's & Dementia | November 10, 2025 | Volume: 21 | Issue: 11 | Pages: No page available

10.1002/alz.70880 | PMID 41208739 Get It

Abstract INTRODUCTION The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site‐level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi‐etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).
Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA ® ) administered via colonoscopy: 6-month data from the sin
Khanna, Sahil , Yoho, David, Handel, Daniel Van, Clark, Brian J., Guthmueller, Beth, Armandi, Daniel, Knapple, W , Safdar, Nasia , Baggott, Brian, Simon, Karen, Knapple, Whitfield , Feuerstadt, Paul , Awad, Tahany , Feuerstadt, Paul

Mayo Clinic

Therapeutic Advances in Gastroenterology | November 10, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251396744 | PMID 41230019 Get It

Background: Fecal microbiota, live-jslm (RBL) is a microbiota-based product for the prevention of recurrent Clostridioides difficile infection (rCDI) in adults following antibiotic treatment. The safety and clinical effectiveness of RBL administered via colonoscopy in adults with rCDI were evaluated in CDI-SCOPE. An 8-week analysis showed 9.8% of participants had RBL-related treatment-emergent adverse events (TEAEs; primary endpoint) and 95.1% experienced treatment success (no CDI recurrence). Objectives: To evaluate long-term safety and clinical effectiveness of RBL through 6 months of follow-up in CDI-SCOPE. Design: Single-arm exploratory phase IIIb trial conducted at 12 sites in the United States. Methods: Eligible adults with rCDI received a single 150-mL dose of RBL to the right colon via colonoscopy. The primary endpoint was RBL-related TEAEs through 8 weeks after RBL administration or confirmed treatment failure. Secondary endpoints included safety up to 6 months after RBL administration. Exploratory analyses included assessment of further CDI episodes. Results: Of the 41 participants enrolled, 39 completed trial assessments through 6 months. From 8 weeks through 6 months after RBL administration, 36 TEAEs in 15 participants (36.6%) were reported, one of which (irritable bowel syndrome) was RBL-related; most TEAEs (97.2%) were of mild or moderate severity. Over the 6-month trial period, 23 participants (56.1%) experienced 69 TEAEs; 94.2% were of mild or moderate severity. Serious TEAEs occurred in three participants (7.3%), none of which were related to RBL or its administration, and no TEAEs led to discontinuation or death. Overall, 38 participants (92.7%) did not experience further CDI episodes, 1 (2.4%) did between 8 weeks and 6 months, and 2 (4.9%) had an indeterminate outcome due to trial withdrawal before 8 weeks. Conclusion: RBL administered via colonoscopy was safe and effective for preventing CDI recurrence in adults with rCDI in CDI-SCOPE. Trial registration: ClinicalTrials.gov: NCT05831189.
Effects of erectile dysfunction and severity of curvature on patient estimation of Peyronie’s disease degree of dorsal curvature
David, Justin , Dalkin, Benjamin, Schommer, Jared , Perry, Alan G., Qosja, Neda, Ferber, Daniel, Baird, Bryce , Perry, Alan, Baird, Bryce A , Broderick, Gregory, Dalkin, Benjamin , Dalkin, Benjamin, Broderick, Gregory A.

Mayo Clinic

The Journal of Sexual Medicine | November 9, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.1093/jsxmed/qdaf313 | PMID 41206917 Get It

Circulating Metabolites Associated with Prothrombin Time and Activated Clotting Time in Children with Congenital Heart Disease: An Untargeted Metabolomics Study
Li, Shengxu , Watson, Dave , Jorgenson, Alissa , Adelekan, Zainab, Garland, Kathleen, Deonovic, Benjamin, Zupancich, Leah, Huntley, Marnie T. , Tang, Weihong , Overman, David M.

Mayo Clinic

No container title available | November 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.11.07.25339794 Get It

Abstract Background Coagulation markers are used to guide clinical anticoagulation decisions. We aimed to identify circulating metabolites that are associated with coagulation markers in children with congenital heart disease (CHD). Methods Plasma samples were separated from whole blood under consistent conditions. Untargeted metabolomic data were measured in plasma from up to 203 young patients (age range: 0 days-24 years) with CHD before cardiac surgery. Coagulation markers included activated partial thromboplastin time (aPTT), prothrombin time (PT), and activated clotting time (ACT). Weighted Gene Co-expression Network Analysis (WGCNA) was performed to explore metabolite modules (clusters). Associations of metabolites with the coagulation markers were assessed cross-sectionally with regression models, with false discovery rate (FDR) correction for multiple comparison. Associations between coagulation markers and ‘eigenmetabolites’ from WGCNA modules were assessed by correlation analysis. Results A total of 776 metabolites were included in the final analysis. Among these, 20 metabolites were associated with PT and one (valine) with ACT (FDR q value < 0.05). Among the metabolites associated with PT, the top three were retinol, 1-palmitoyl-GPI (16:0), and X-25371 (identity unknown). One module from WGCNA with metabolites from the lipid super pathway was correlated with PT (P = 0.004). Conclusion In this first attempt to identify novel metabolites for coagulation markers, we report 21 metabolites associated with PT or ACT in children with CHD. Future studies are needed to replicate these findings in independent cohorts and to elucidate the biological mechanisms linking these metabolites to hemostatic regulation.
NODG-01 EVALUATING THE CURRENT NEURO-ONCOLOGY CAPACITY IN SUB-SAHARAN AFRICA: A QUESTIONNAIRE-BASED SURVEY
Zerd, Francis , Cheserem, Beverly , Ghomsi, Nathalie , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Schroeder, Kristin, Zerd, Francis , Odukoya, Lateef A , Darko, Kwadwo , LLEWELLYN, HENRY J. , Kamson, David , Fonkem, Ekokobe , Schroeder, Kristin

Mayo Clinic

Neuro-Oncology Advances | November 9, 2025 | Volume: 7 | Issue: Supplement_5 | Pages: No page available

10.1093/noajnl/vdaf213.046 Get It

Abstract Background Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in sub-Saharan Africa (SSA). To date, no large-scale efforts have focused on brain tumor genetics within this region. This study aimed to assess and map the current neuro-oncology capacity in SSA, including workforce availability and existing services for brain tumor registries and biobanks. The results represent the final analysis representing respondents from 70 healthcare institutions. Methods This cross-sectional study utilized an online survey to collect data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey gathered information on the availability of neuro-oncology practitioners, neuropathology and molecular diagnostic capacity, brain tumor management, cancer registries, and biobanking of specimens. Purposive sampling was used to identify participants, with the questionnaire provided in English, French, and Swahili. Results A total of 145 respondents from 22 countries and 70 healthcare institutions participated. Among the 70 institutions, neurosurgery was available in 89%, anatomic pathology in 74%, and medical oncology in 71%. For radiologic evaluation, 64% of institutions reported having both CT and MRI, while 17% had CT only. Molecular testing through IHC or NGS was available in 46% of institutions. Multidisciplinary tumor boards for CNS cases were present in 86% of institutions. General cancer registries were available in 66% of institutions, while 29% had brain tumor-specific registries, and 10% maintained brain tumor biorepositories. Conclusion This study provides a comprehensive summary of the neuro-oncology capacity in SSA. Next steps are to reach out to institutions who have registries and determine what data are being collected, with the hopes of defining a set of common elements to expand registry efforts across SSA. Similarly, to reach out to institutions that have ongoing brain tumor biobanks and CT/MRI capacity to determine what infrastructure exists.
Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship
Paras, Molly L , Stead, Wendy , Bisono, Bismarck , Pottinger, Paul S. , Aziz, Rania S Abdel, Aziz, Mariam, Balba, Gayle , Blackburn, Brian G. , Butt, Saira , Chow, Brian , Graber, Christopher J. , Muñoz-Gómez, Sigridh , Pellegrino, Rachael , Schultz, Sara , Shnekendorf, Rachel, Jezek, Amanda, Martin, Allan , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Angarone, Michael , Arnold, Forest, Bartash, Rachel , Bhanot, Nitin , Bhatt, Pinki J. , Bittner, Marvin J. , Blyth, Dana M , Carey, A., Cerne, Carlie, Donaghy, Henry, Echevarria, Leonor, Jose, Jo-Ann, Kodiyanplakkal, Rosy Priya , Román, F, Garcia, Luis Medina, Lora, Alfredo J Mena , Miko, Benjamin A. , Mitra, Subhashis , Osorio, Georgina, Patel, Mukesh, Pinargote, Paulette, Salas, Natalie Mariam , Sellers, Christopher J., Tang, Michael , Tischendorf, Jessica S , Trinh, Sonya, Viehman, J Alex, Vielemeyer, Ole, Wooten, Darcy , Bisono Garcia, Bismarck , Martin, Arlene , Luther, Vera P , Pottinger, Paul , Aziz, Rabita, Luther, Vera , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Arnold, Forest, Bhowmick, Tanaya , Carey, Adrienne L, Dare, Ryan K , Jose, Jo-Ann, Gil, Raul Macias , Roman, Francisco Machiavello, Garcia, Luis Medina, Razonable, Raymund R. , Trinh, Sonya, Viehman, J Alex

Mayo Clinic

Open Forum Infectious Diseases | November 9, 2025 | Volume: 12 | Issue: 12 | Pages: No page available

10.1093/ofid/ofaf677 | PMID 41322240 Get It

Abstract Advocacy has long been at the core of the infectious diseases (ID) field, with clinicians and researchers advocating to ensure patients can access the care they need on an individual and global scale. The Infectious Diseases Society of America Training Program Directors’ (PD) Committee met in 2024 and discussed ways that advocacy is and should be incorporated into fellowship training, as well as highlighted the role PDs play in advocating for their trainees. Policies with a negative impact on ID clinical care, public health, and research underscore the importance of mobilizing the field of ID to advocate for the patients and communities we serve, as well as for ourselves. This paper presents ideas generated at this meeting and is meant to serve as a reference for ID PDs, as well as the wider ID community, as a call to action for teaching and participating in advocacy work.
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
Davis, Margot K. , Akinboboye, Olakunle O., Bhatt, Kunal , Fontana, Marianna, Gillmore, Julian D., Griffin, Jan M. , Grodin, Justin L. , Lam, Kaitlyn, Masri, Ahmad , Ruberg, Frederick L. , Sarswat, N., Shah, Keyur B. , Soman, Prem, Xiong, Kuangnan, Cao, Xiaofan, Lystig, Ted, Tamby, Jean‐François, Castaño, Adam , Katz, Leonid , Sinha, Uma, Fox, Jonathan C., Solomon, Scott D. , Grogan, Martha, Gillmore, Julian D , Alexander, Kevin M , Berk, John L. , Cappelli, Francesco, Cuddy, Sarah A. M. , Fontana, Marianna , Garcia-Pavia, Pablo , Gillmore, Julian D. , Judge, Daniel P. , Khouri, Michel G. , Maurer, Matthew J. , Obici, Laura , Soman, Prem , Stern, Lily Kagan , Wright, Richard, Lystig, Ted, Solomon, Scott David , Grogan, Martha

Mayo Clinic

JAMA Cardiology | November 8, 2025 | Volume: 11 | Issue: 1 | Pages: 57

10.1001/jamacardio.2025.4477 | PMID 41205147 Get It

Importance Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE). Objective To evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile). Design, Setting, and Participants This international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025. Interventions Oral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment. Main Outcomes and Measures All-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile. Results Overall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42. Conclusions and Relevance The beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups. Trial Registration ClinicalTrials.gov Identifiers: NCT03860935 ; NCT04988386
Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes
Allam, Mohamed , Abdelnabi, Mahmoud , Sorajja, Dan , Fortuin, F. David , Bhakta, Mayurkumar D. , Pathangey, Girish , Allam, Mohamed N , Abdelnabi, Mahmoud H., Sorajja, Dan , Fortuin, Floyd David , Bhakta, Mayurkumar D , Pathangey, Girish , Lee, Kwan

Mayo Clinic

Journal of Clinical Medicine | November 7, 2025 | Volume: 14 | Issue: 22 | Pages: 7910

10.3390/jcm14227910 | PMID 41302946 Get It

Despite advances in lipid-lowering and antithrombotic therapy, patients with acute coronary syndromes remain at elevated risk for recurrent events due to persistent atherosclerotic inflammation. This review evaluates inflammation as a therapeutic target in secondary prevention and discusses established, investigational, and emerging strategies. Colchicine, now FDA-approved for cardiovascular risk reduction, lowered major adverse cardiovascular events in COLCOT and LoDoCo2. Canakinumab (IL-1β inhibition) reduced recurrent events in proportion to IL-6 and hsCRP suppression, while ziltivekimab (IL-6 inhibition) achieved profound biomarker reductions but remains investigational. Early-phase studies of anakinra (IL-1 receptor antagonist) and dapansutrile (oral NLRP3 inhibitor) showed anti-inflammatory effects in early trials, whereas varespladib and darapladib illustrated the challenges of targeting lipid-associated pathways. Beyond direct immunomodulators, GLP-1 receptor agonists and SGLT2 inhibitors provide both cardioprotective and anti-inflammatory benefits, reinforcing their expanding role post-ACS. Additional emerging avenues include triptolidiol, dasatinib, and BTK or JAK/STAT inhibitors, while novel approaches, such as nanozyme delivery systems and CRISPR-based editing, extend the therapeutic horizon. This review highlights the potential of inflammation-targeted therapies to advance secondary prevention in ACS by integrating current evidence and perspectives on future therapeutic developments.
Eosinophil peroxidase induces inflammation in a mouse model of dermatitis
Roth‐Carter, Quinn R. , Kornfield, James , Luo, Huijun , Ochkur, Sergei I. , Lee, James J. , Jacobsen, Elizabeth A. , Fryer, A.D. , Jacoby, David B.

Mayo Clinic

Journal of Leukocyte Biology | November 7, 2025 | Volume: 118 | Issue: 1 | Pages: No page available

10.1093/jleuko/qiaf158 | PMID 41206714 Get It

Abstract Eosinophils play an important role in mediating itch and inflammation in dermatitis. The role of the eosinophil granule protein eosinophil peroxidase (EPX) in mediating inflammation and itch was tested in a dermatitis mouse model. Mice were sensitized to trimellitic anhydride (TMA) and subsequently challenged chronically on the ear to establish dermatitis. Loss of EPX (in EPX−/− mice) or blocking EPX with the drug resorcinol significantly reduced dermatitis in mice exposed to TMA. Resorcinol also reduced levels of thymic stromal lymphopoietin protein (TSLP) in skin. Further studies showed that EPX increased different cytokines in keratinocytes in cell culture via 2 distinct mechanisms. EPX-induced TSLP expression requires lysophosphatidic acid signaling while EPX-induced expression of TNF-α, CSF2, CSF3, and IL1a required IL-1 signaling. We also showed that blocking IL-1 reduced inflammation in skin following TMA exposure in mice. Thus, EPX is an important mediator of inflammation and itch, that are mediated via at least 2 pathways. This suggests that both EPX and its signaling pathways may provide novel therapeutic strategies in dermatitis.
Esophageal Screening During the Videofluoroscopic Swallow Study: Roadblocks and Roadmaps
Watts, Stephanie , Gregor, Jessica W. , Miles, Anna , Vela, Marcelo F. , Jain, Anand , Yokum, Michael, Belafsky, Peter C. , Co-Lab, the Esophageal, Watts, Stephanie A., Lott, David G. , Kahn, Allon , Tritter, Andrew G. , Gregor, Jessica W

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | November 6, 2025 | Volume: 10 | Issue: 6 | Pages: 2049-2060

10.1044/2025_persp-25-00143 Get It

Purpose: There are reported barriers to implementation of esophageal screening during the videofluoroscopic swallow study (VFSS) completed by the speech-language pathologist (SLP). Often, patients referred to the SLP for a VFSS have an esophageal component that may explain their complaint. In this article, authors explore roadblocks to esophageal screening and potential roadmaps to improve patient care through standardization of esophageal screening procedures. Conclusions: A strong body of literature supports physiologic, anatomic, and disease state relationships of the oropharynx and esophagus. Despite this, the assessment of the oropharynx and esophagus is dichotomized. There remain billing limitations for same-day esophagram and VFSS, and the well-documented esophageal screen provides a view of bolus flow in an upright, typical eating position with consideration of oropharyngeal function to provide a comprehensive view of the continuous process of swallowing from mouth to stomach. The continued practice of evaluating the oropharynx without consideration of the esophagus poses a threat to patient safety and may delay care. A collaborative, multidisciplinary effort among healthcare professionals to create streamlined practice parameters, update position statements, and enhance education parameters will allow for cohesive practices among professionals. Assessment of the swallow mechanism is incomplete without consideration of the entire continuum.